Viking Therapeutics, Inc. (VKTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Viking Therapeutics said VK2735 delivered approximately 15% weight loss from baseline after 13 weeks in its completed Phase II obesity study. The company has advanced the weekly injectable candidate into two fully enrolled Phase III trials, VANQUISH-1 in obesity and VANQUISH-2 in obesity with Type 2 diabetes, with data expected in the second half of 2027. The update supports continued momentum in Viking's obesity pipeline, though the key value inflection remains dependent on longer-term Phase III results.

Analysis

VKTX’s value is now dominated by a single binary probability tree rather than near-term operating execution. Full enrollment removes recruitment risk but does not validate durability, discontinuation rates, glycemic outcomes, or tolerability at commercially relevant maintenance dosing; cross-trial comparisons to Eli Lilly’s tirzepatide remain a poor basis for assigning parity. With efficacy leadership increasingly insufficient on its own, the eventual commercial bar is likely differentiated tolerability, supply reliability, and payer access—areas where LLY and Novo Nordisk (NVO) retain substantial structural advantages.

The next 1-3 months lack a hard clinical catalyst, making conference-driven strength vulnerable to profit-taking and biotech-factor moves. Over the next 6-18 months, the critical variables are cash runway through the Phase III readouts, manufacturing/CMC updates, and whether management provides credible commercialization financing plans; equity issuance before data would increase the discount rate applied to a 2027 outcome. A broad GLP-1 reimbursement expansion would lift the category but could also raise the evidence threshold for late entrants as payers demand outcomes data and net-price concessions.

Consensus may underweight the strategic value of a clean, competitive dataset: a credible Phase III profile could make VKTX a logical acquisition or licensing asset for a company seeking obesity exposure, supporting a higher takeout floor than standalone launch economics imply. Conversely, that optionality is not sufficient reason to pay up before data; obesity M&A buyers can wait for confirmation while incumbents continue to improve oral, injectable, and next-generation combination offerings. Thesis falsification for a bullish stance is any signal of incremental capital need, weaker-than-expected retention, or a competitor establishing clearly superior efficacy/tolerability before VKTX’s readout window.

Key Decisions for Investors

• Do not chase VKTX on conference commentary; treat it as a watch-list event name until updated cash-burn, manufacturing, and financing guidance establishes runway beyond the Phase III data window. Reassess after the next quarterly filing or any capital-markets announcement.
• For investors requiring obesity exposure over the next 6-12 months, prefer LLY over VKTX: LLY has revenue-generating supply, payer infrastructure, and multiple near-term execution catalysts, while VKTX carries concentrated pre-data clinical and financing risk. Use a VKTX long only after a material pullback or independently verifiable operational de-risking.
• If VKTX appreciates materially without new clinical data, consider a tactical short VKTX versus long LLY basket over a 1-3 month horizon; the trade monetizes catalyst scarcity and relative multiple risk. Cover on announced strategic financing, partnership/M&A indications, or material Phase III timing acceleration.
• Set alerts for: cash runway falling short of late-2027 readout needs, any equity/convert issuance, Phase III discontinuation or dose-modification disclosure, and LLY/NVO competitor data that reset the efficacy or tolerability benchmark. Any of these would warrant reducing VKTX probability-of-success assumptions.